Q-omics provides the consensus-scored RPL15P14 profile across patient tissues and cancer cell-line models. RPL15P14 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, RPL15P14 is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, RPL15P14 RNA expression shows 8,382 significant protein co-abundance associations, with the highest sampling consensus in OV. Together, these results highlight SKCM, COAD, and OV as cancer lineages where RPL15P14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL15P14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL15P14 survival associations across molecular data types. RPL15P14 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL15P14 RNA expression–survival associations across cancer types. High RPL15P14 expression shows unfavorable associations in ACC, KICH, MESO, LIHC and SARC, but favorable associations in SKCM. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for RPL15P14 RNA expression.
This table summarizes RPL15P14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL15P14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL15P14 shows higher tumor expression in COAD, LUAD, PRAD, LIHC and KIRP. The COAD box plot shows higher RPL15P14 RNA expression in tumor versus normal tissue (log2 FC = +0.303, t-test p = .025).
This table shows molecular features associated with RPL15P14 in patient tissues and cancer cell lines. In patient samples, RPL15P14 shows the broadest associations at the RNA and protein expression levels, with OV recurring as the lineage with the largest associated feature set.
